![Janux Therapeutics Inc](/common/images/company/N_JANX.png)
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer. Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for expansion cohorts is...
Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 3.58 | 8.48743480322 | 42.18 | 48.9399 | 41.28 | 632556 | 43.84266893 | CS |
4 | 5.75 | 14.3714071482 | 40.01 | 48.9399 | 37.72 | 651350 | 41.68181078 | CS |
12 | -4.19 | -8.38838838839 | 49.95 | 65.6 | 37.72 | 796214 | 48.31682941 | CS |
26 | 36.32 | 384.745762712 | 9.44 | 65.6 | 7.79 | 828305 | 45.60866368 | CS |
52 | 32.9 | 255.832037325 | 12.86 | 65.6 | 5.65 | 462107 | 41.50008915 | CS |
156 | 19.44 | 73.8601823708 | 26.32 | 65.6 | 5.65 | 225774 | 34.11137087 | CS |
260 | 11.76 | 34.5882352941 | 34 | 65.6 | 5.65 | 229423 | 33.64249783 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.